Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Recro Pharma Inc (REPH)

Recro Pharma Inc (REPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,926
  • Shares Outstanding, K 56,424
  • Annual Sales, $ 75,360 K
  • Annual Income, $ -11,370 K
  • 60-Month Beta 1.08
  • Price/Sales 1.57
  • Price/Cash Flow N/A
  • Price/Book 2.33
Trade REPH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 05/05/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +82.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +37.50%
on 02/24/22
2.19 -4.57%
on 03/18/22
+0.49 (+30.62%)
since 02/18/22
3-Month
1.42 +47.18%
on 01/31/22
2.19 -4.57%
on 03/18/22
+0.55 (+35.71%)
since 12/21/21
52-Week
1.38 +51.45%
on 12/06/21
3.79 -44.85%
on 03/22/21
-1.48 (-41.46%)
since 03/19/21

Most Recent Stories

More News
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers’ Goal of...

REPH : 2.09 (-0.48%)
Recro Reports Fourth Quarter and Year End 2021 Financial Results

Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele ...

REPH : 2.09 (-0.48%)
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern...

REPH : 2.09 (-0.48%)
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention

SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing...

REPH : 2.09 (-0.48%)
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego

Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations...

REPH : 2.09 (-0.48%)
Recro to Present at H.C. Wainwright BioConnect 2022 Conference

SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing...

REPH : 2.09 (-0.48%)
Recro Pharma: Q3 Earnings Snapshot

EXTON, Pa. (AP) _ Recro Pharma Inc. (REPH) on Tuesday reported a loss of $3.5 million in its third quarter.

REPH : 2.09 (-0.48%)
Recro Reports Third Quarter 2021 Financial Results

Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and...

REPH : 2.09 (-0.48%)
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka

Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as...

REPH : 2.09 (-0.48%)
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic

New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIH...

REPH : 2.09 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough...

See More

Key Turning Points

3rd Resistance Point 2.29
2nd Resistance Point 2.22
1st Resistance Point 2.15
Last Price 2.09
1st Support Level 2.01
2nd Support Level 1.94
3rd Support Level 1.87

See More

52-Week High 3.79
Fibonacci 61.8% 2.87
Fibonacci 50% 2.59
Fibonacci 38.2% 2.30
Last Price 2.09
52-Week Low 1.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar